TL/DR –
The biotechnology industry in the U.S., despite being a crucial component of modern healthcare and medicine production, is facing strain as it is forced to operate within structures designed for pharmaceuticals rather than biotech. The two industries, while both essential, operate under fundamentally different constraints, with biotech centered on discovery and pharma on delivery. The forced alignment of the two has led to a misalignment of the system, financial strain on biotech companies, and an erosion of the U.S.’s lead in science, with countries like China taking a more deliberate approach to supporting their biotech sector.
“`html
The biotechnology industry, a cornerstone of healthcare innovation and the prime source of new medicines in the United States, is defined by its inherent connection to scientific discovery. The biotech sector, which started in the mid-1970s, was seen as an unpredictable and fragmented entity by many pharmaceutical companies. This, however, was a miscalculation given how vital biotech has become today.
Biotech functions as the driver of discovery, carrying out extensive research and producing crucial insights, while pharmaceuticals take the ready knowledge and scale it. Both industries are crucial but operate under different circumstances and pressures. However, as biotech evolved from a handful of companies to thousands, the systems and structures that supported it did not adapt to these changes.
Instead, the risk-laden and dynamic nature of biotech was forcibly fit into the predictable and operationally certain frameworks that were designed for pharmaceutical companies. This has led to a structural misalignment that became apparent when Martin Shkreli, the then CEO of Turing Pharmaceuticals, drastically increased the price of Daraprim in 2015. The political backlash that ensued affected biotech companies that had no connection to this event.
Biotech was now subject to pharma’s political risk without sharing its revenue base.
The event was a clear indicator that the distinction between discovery-stage biotech and commercial pharmaceutical companies had blurred substantially. Biotech was being subjected to the political risks that pharmaceutical companies faced, but without a similar revenue base.
A central fault line
While both biotech and pharma involve uncertainty, pharmaceutical companies can manage failures and setbacks due to their scale, revenue, and diversification. Biotech companies, on the other hand, often hinge on a single scientific insight or platform and are far from revenue generation. Despite this, there is an expectation for biotech companies to behave as predictable businesses, resulting in a systemic tension that is becoming more visible.
For instance, at biotech conferences, discussions on pricing, Inflation Reduction Act negotiations, and tariffs overshadow the fact that many biotech firms are pre-revenue discovery companies. With these misaligned expectations, political and reimbursement uncertainties have started to overshadow the scientific uncertainties that originally defined biotech.
A strategic misstep
The fallout of this systemic issue is immediate. Funding has tightened sharply, causing delays and forcing some promising projects to be abandoned. The institutions that underpin the industry—the National Institutes of Health, the FDA, and the National Science Foundation—are facing funding cuts, workforce losses, and weakened oversight. This is causing a decline in confidence in long-term scientific investment, leading to fewer experiments and discoveries.
The U.S. still leads in science, but other countries like China have been more deliberate. China has aligned its capital, policy, and infrastructure to treat biotechnology as a strategic sector. As a result, trials, capital, and talent are increasingly moving to China.
For the U.S. to retain its leadership in biotechnology, there needs to be a structural response. Capital markets need to align with long-cycle innovation. Public institutions must be stabilized and strengthened. Policymakers must treat biotech as a strategic capability and not just a pricing debate. Until such changes are made, the political problems of pharma will continue to determine the future of biotech.
“`
—
Read More US Economic News